An Open-label, Multiple Dose, Parallel Group, Phase I Study to Assess the Pharmacokinetics and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Midostaurin (Primary)
- Indications Acute myeloid leukaemia
- Focus Pharmacokinetics
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 01 Mar 2017 Planned End Date changed from 22 Mar 2017 to 30 May 2018.
- 01 Mar 2017 Planned primary completion date changed from 22 Mar 2017 to 30 May 2018.